| Project/Area Number |
25670085
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Sojo University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MARUYAMA Toru 熊本大学, 薬学部, 教授 (90423657)
WATANABE Hiroshi 熊本大学, 薬学部, 准教授 (70398220)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | アルブミン / リポソーム / 骨髄指向性 / デリバリーシステム / 体内動態解析 / 薬力学的評価 / 抗がん剤 / 腫瘍治療効果 |
|---|
| Outline of Final Research Achievements |
This research aims to construct an anticancer drug delivery system using bone marrow-directed liposome as a carrier, and explore its clinical application in malignant tumors’ bone metastasis treatment. The drug was incorporated in the bone marrow directed liposome for physicochemical, pharmacological efficacy and pharmacokinetic properties examinations. As such, erythropoietin (EPO) liposome was produced to effectively and selectively deliver EPO to its site of action in bone marrow. The formulation characteristics, transferability to bone marrow, and hematopoietic effect were being examined. In comparison to EPO alone which did not demonstrate any desirable effects, liposome formulation was found to have produced significant site directed delivery improvement effect.
|
